IS2568B - Kínasólínafleiður sem SRC týrósínkínasatálmar - Google Patents

Kínasólínafleiður sem SRC týrósínkínasatálmar

Info

Publication number: IS2568B
Authority: IS; Iceland
Prior art keywords: tyrosine kinase; kinase inhibitors; quinazoline derivatives; src tyrosine; src
Prior art date: 2002-11-04

Application number

IS7849A

Other languages

English (en)

Other versions

IS7849A (is

Inventor

Patrick Ple

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-04

Filing date

2005-05-19

Publication date

2010-01-15

2005-05-19 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2005-05-19 Publication of IS7849A publication Critical patent/IS7849A/is

2010-01-15 Publication of IS2568B publication Critical patent/IS2568B/is

Links

125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
102000009076 src-Family Kinases Human genes 0.000 title 1
108010087686 src-Family Kinases Proteins 0.000 title 1
229940121358 tyrosine kinase inhibitor Drugs 0.000 title 1
239000005483 tyrosine kinase inhibitor Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Life Sciences & Earth Sciences (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Immunology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Ophthalmology & Optometry (AREA)
Vascular Medicine (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pain & Pain Management (AREA)
Oncology (AREA)
Dermatology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

IS7849A 2002-11-04 2005-05-19 Kínasólínafleiður sem SRC týrósínkínasatálmar IS2568B (is)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP02292736		2002-11-04
EP03290900		2003-04-10
PCT/GB2003/004703 WO2004041829A1 (en)	2002-11-04	2003-10-29	Quinazoline derivatives as src tyrosine kinase inhibitors

Publications (2)

Publication Number	Publication Date
IS7849A IS7849A (is)	2005-05-19
IS2568B true IS2568B (is)	2010-01-15

Family

ID=32313852

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS7849A IS2568B (is)	2002-11-04	2005-05-19	Kínasólínafleiður sem SRC týrósínkínasatálmar

Country Status (27)

Country	Link
US (1)	US7462623B2 (is)
EP (1)	EP1562955B1 (is)
JP (2)	JP4593464B2 (is)
KR (1)	KR101089462B1 (is)
AR (1)	AR041884A1 (is)
AT (1)	ATE387451T1 (is)
AU (1)	AU2003278383B2 (is)
BR (1)	BR0315756A (is)
CA (1)	CA2503371C (is)
CO (1)	CO5560578A2 (is)
CY (1)	CY1108061T1 (is)
DE (1)	DE60319410T2 (is)
DK (1)	DK1562955T3 (is)
EG (1)	EG24957A (is)
ES (1)	ES2300619T3 (is)
IL (1)	IL168013A (is)
IS (1)	IS2568B (is)
MX (1)	MXPA05004858A (is)
MY (1)	MY137835A (is)
NO (1)	NO331951B1 (is)
NZ (1)	NZ539408A (is)
PL (1)	PL215161B1 (is)
PT (1)	PT1562955E (is)
RU (1)	RU2350618C2 (is)
SI (1)	SI1562955T1 (is)
TW (1)	TWI320786B (is)
WO (1)	WO2004041829A1 (is)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1521747B1 (en)	2002-07-15	2018-09-05	Symphony Evolution, Inc.	Receptor-type kinase modulators and methods of use
EP2210607B1 (en)	2003-09-26	2011-08-17	Exelixis Inc.	N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
GB0406445D0 (en) *	2004-03-23	2004-04-28	Astrazeneca Ab	Combination therapy
GB0427697D0 (en) *	2004-12-17	2005-01-19	Astrazeneca Ab	Chemical process
NZ556673A (en) *	2005-02-03	2010-03-26	Gen Hospital Corp	Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor
WO2009068906A2 (en) *	2007-11-26	2009-06-04	Astrazeneca Ab	Combinations comprising zd4054 and a src family kinase inhibitor 172
TW201920110A (zh)	2009-01-16	2019-06-01	美商艾克塞里克斯公司	包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
UA108618C2 (uk)	2009-08-07	2015-05-25		Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
HUE045810T2 (hu)	2010-09-27	2020-01-28	Exelixis Inc	MET és VEGF kettõs inhibitorai kasztrációrezisztens prosztatarák és oszteoblasztos csontáttétek kezelésére
AR092289A1 (es) *	2011-11-14	2015-04-15	Sunshine Lake Pharma Co Ltd	Derivados de aminoquinazolina y sus sales y metodos de uso
US20190112317A1 (en)	2015-10-05	2019-04-18	The Trustees Of Columbia University In The City Of New York	Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
US10722484B2 (en)	2016-03-09	2020-07-28	K-Gen, Inc.	Methods of cancer treatment
WO2020055755A1 (en)	2018-09-10	2020-03-19	Mirati Therapeutics, Inc.	Combination therapies
CN119504612B (zh) *	2024-11-18	2026-04-07	中国海洋大学	一种喹唑啉茋类衍生物及其制备方法和应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5721237A (en)	1991-05-10	1998-02-24	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5710158A (en) *	1991-05-10	1998-01-20	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5480883A (en) *	1991-05-10	1996-01-02	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
DE69222637T2 (de) *	1991-05-10	1998-02-26	Rhone Poulenc Rorer Int	Bis mono- und bicyclische aryl- und heteroarylderivate mit inhibierender wirkung auf die egf und/oder pdgf-rezeptor tyrosinkinase
PT100905A (pt) *	1991-09-30	1994-02-28	Eisai Co Ltd	Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
AU661533B2 (en) *	1992-01-20	1995-07-27	Astrazeneca Ab	Quinazoline derivatives
GB9205320D0 (en) *	1992-03-11	1992-04-22	Ici Plc	Anti-tumour compounds
GB9323290D0 (en) *	1992-12-10	1994-01-05	Zeneca Ltd	Quinazoline derivatives
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
GB9508538D0 (en) *	1995-04-27	1995-06-14	Zeneca Ltd	Quinazoline derivatives
US6046206A (en) *	1995-06-07	2000-04-04	Cell Pathways, Inc.	Method of treating a patient having a precancerous lesions with amide quinazoline derivatives
GB9514265D0 (en) *	1995-07-13	1995-09-13	Wellcome Found	Hetrocyclic compounds
GB9624482D0 (en) *	1995-12-18	1997-01-15	Zeneca Phaema S A	Chemical compounds
CA2242425C (en) *	1996-02-13	2006-07-18	Zeneca Limited	Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) *	1996-02-14	1996-04-10	Zeneca Ltd	Quinazoline derivatives
NZ331191A (en)	1996-03-05	2000-03-27	Zeneca Ltd	4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
EP0888310B1 (en) *	1996-03-15	2005-09-07	AstraZeneca AB	Cinnoline derivatives and use as medicine
GB9707800D0 (en) *	1996-05-06	1997-06-04	Zeneca Ltd	Chemical compounds
US6391874B1 (en)	1996-07-13	2002-05-21	Smithkline Beecham Corporation	Fused heterocyclic compounds as protein tyrosine kinase inhibitors
GB9718972D0 (en) *	1996-09-25	1997-11-12	Zeneca Ltd	Chemical compounds
CN1252054C (zh)	1996-09-25	2006-04-19	曾尼卡有限公司	抑制生长因子的作用的喹啉衍生物
DE69838172T2 (de)	1997-08-22	2008-04-10	Astrazeneca Ab	Oxindolylchinazolinderivate als angiogenesehemmer
CZ303899B6 (cs)	1998-09-29	2013-06-19	Wyeth Holdings Corporation	Substituovaný 3-kyanochinolin, zpusob jeho prípravy a farmaceutická kompozice s jeho obsahem
ES2241324T3 (es)	1998-10-08	2005-10-16	Astrazeneca Ab	Derivados de quinazolina.
EE05345B1 (et) *	1999-02-10	2010-10-15	Astrazeneca Ab	Kinasoliini derivaadid angiogeneesi inhibiitoritena
HK1046688A1 (zh)	1999-09-21	2003-01-24	Astrazeneca Ab	喹唑啉化合物和含有喹唑啉化合物的藥物組合物
GB9922171D0 (en)	1999-09-21	1999-11-17	Zeneca Ltd	Chemical compounds
PT1244647E (pt) *	1999-11-05	2006-10-31	Astrazeneca Ab	Derivados de quinazolina como inibidores de vegf
AU2001235804A1 (en)	2000-03-06	2001-09-17	Astrazeneca Ab	Therapy
GB0008269D0 (en)	2000-04-05	2000-05-24	Astrazeneca Ab	Combination chemotherapy
IL151626A0 (en)	2000-04-07	2003-04-10	Astrazeneca Ab	Quinazoline compounds
UA73993C2 (uk) *	2000-06-06	2005-10-17	Астразенека Аб	Хіназолінові похідні для лікування пухлин та фармацевтична композиція
IL153805A0 (en) *	2000-08-09	2003-07-31	Astrazeneca Ab	Cinnoline compounds
US20030207878A1 (en)	2000-08-09	2003-11-06	Hennequin Lawrent Francois Andre	Chemical compounds
WO2002012226A1 (en)	2000-08-09	2002-02-14	Astrazeneca Ab	Quinoline derivatives having vegf inhibiting activity
AU2001278609B2 (en) *	2000-08-21	2005-04-14	Astrazeneca Ab	Quinazoline derivatives
WO2002030924A1 (en)	2000-10-13	2002-04-18	Astrazeneca Ab	Quinazoline derivatives with anti-tumour activity
WO2002030926A1 (en)	2000-10-13	2002-04-18	Astrazeneca Ab	Quinazoline derivatives
US20040063733A1 (en)	2000-10-25	2004-04-01	Lambert Christine Marie Paul	Quinazoline derivatives
ATE409185T1 (de) *	2001-04-19	2008-10-15	Astrazeneca Ab	Chinazolin derivate
WO2002092579A1 (en)	2001-05-14	2002-11-21	Astrazeneca Ab	4-anilinoquinazoline derivatives
WO2002092578A1 (en)	2001-05-14	2002-11-21	Astrazeneca Ab	Quinazoline derivatives
WO2002092577A1 (en)	2001-05-14	2002-11-21	Astrazeneca Ab	Quinazoline derivatives
ES2272737T3 (es)	2001-07-16	2007-05-01	Astrazeneca Ab	Derivados de quinolina y su uso como inhibidores de tirosina quinasas.
GB0126879D0 (en)	2001-11-08	2002-01-02	Astrazeneca Ab	Combination therapy
AU2002365664A1 (en)	2001-12-05	2003-06-17	Astrazeneca Ab	Quinoline derivatives as antitumour agents
EP2292615A1 (en) *	2002-02-01	2011-03-09	AstraZeneca AB	Quinazoline compounds
GB0215823D0 (en)	2002-07-09	2002-08-14	Astrazeneca Ab	Quinazoline derivatives
EP1528925B1 (en)	2002-07-09	2009-04-22	Astrazeneca AB	Quinazoline derivatives for use in the treatment of cancer
AU2003249000B2 (en)	2002-08-09	2007-04-05	Astrazeneca Ab	Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0218526D0 (en)	2002-08-09	2002-09-18	Astrazeneca Ab	Combination therapy
GB0223380D0 (en)	2002-10-09	2002-11-13	Astrazeneca Ab	Combination therapy
GB0226434D0 (en) *	2002-11-13	2002-12-18	Astrazeneca Ab	Combination product
DE602004032310D1 (de)	2003-02-13	2011-06-01	Astrazeneca Ab	Kombinationstherapie von zd6474 mit 5-fu oder/und cpt-11
GB0310401D0 (en) *	2003-05-07	2003-06-11	Astrazeneca Ab	Therapeutic agent

2003
- 2003-10-29 RU RU2005117337/04A patent/RU2350618C2/ru not_active IP Right Cessation
- 2003-10-29 JP JP2005502127A patent/JP4593464B2/ja not_active Expired - Fee Related
- 2003-10-29 MX MXPA05004858A patent/MXPA05004858A/es active IP Right Grant
- 2003-10-29 WO PCT/GB2003/004703 patent/WO2004041829A1/en not_active Ceased
- 2003-10-29 KR KR1020057007855A patent/KR101089462B1/ko not_active Expired - Fee Related
- 2003-10-29 ES ES03769689T patent/ES2300619T3/es not_active Expired - Lifetime
- 2003-10-29 EP EP03769689A patent/EP1562955B1/en not_active Expired - Lifetime
- 2003-10-29 CA CA2503371A patent/CA2503371C/en not_active Expired - Fee Related
- 2003-10-29 PT PT03769689T patent/PT1562955E/pt unknown
- 2003-10-29 DK DK03769689T patent/DK1562955T3/da active
- 2003-10-29 US US10/533,931 patent/US7462623B2/en not_active Expired - Fee Related
- 2003-10-29 AU AU2003278383A patent/AU2003278383B2/en not_active Ceased
- 2003-10-29 BR BR0315756-3A patent/BR0315756A/pt not_active IP Right Cessation
- 2003-10-29 NZ NZ539408A patent/NZ539408A/en not_active IP Right Cessation
- 2003-10-29 DE DE60319410T patent/DE60319410T2/de not_active Expired - Lifetime
- 2003-10-29 AT AT03769689T patent/ATE387451T1/de active
- 2003-10-29 SI SI200331192T patent/SI1562955T1/sl unknown
- 2003-10-29 PL PL376255A patent/PL215161B1/pl unknown
- 2003-10-30 TW TW092130284A patent/TWI320786B/zh not_active IP Right Cessation
- 2003-11-03 MY MYPI20034197A patent/MY137835A/en unknown
- 2003-11-04 AR ARP030104036A patent/AR041884A1/es not_active Application Discontinuation
2005
- 2005-04-13 IL IL168013A patent/IL168013A/en not_active IP Right Cessation
- 2005-04-19 NO NO20051900A patent/NO331951B1/no not_active IP Right Cessation
- 2005-04-30 EG EGNA2005000178 patent/EG24957A/xx active
- 2005-05-03 CO CO05042313A patent/CO5560578A2/es not_active Application Discontinuation
- 2005-05-19 IS IS7849A patent/IS2568B/is unknown
2008
- 2008-04-24 CY CY20081100460T patent/CY1108061T1/el unknown
2010
- 2010-07-26 JP JP2010167576A patent/JP2010270143A/ja active Pending

Also Published As

Publication number	Publication date
US20060122199A1 (en)	2006-06-08
IL168013A (en)	2013-03-24
SI1562955T1 (sl)	2008-06-30
PL376255A1 (en)	2005-12-27
JP2010270143A (ja)	2010-12-02
RU2005117337A (ru)	2006-01-20
NO20051900L (no)	2005-06-01
PT1562955E (pt)	2008-05-05
HK1079195A1 (en)	2006-03-31
CA2503371C (en)	2011-01-11
PL215161B1 (pl)	2013-10-31
JP4593464B2 (ja)	2010-12-08
RU2350618C2 (ru)	2009-03-27
NZ539408A (en)	2007-09-28
CY1108061T1 (el)	2014-02-12
JP2006506463A (ja)	2006-02-23
CO5560578A2 (es)	2005-09-30
CA2503371A1 (en)	2004-05-21
TWI320786B (en)	2010-02-21
NO331951B1 (no)	2012-05-14
MY137835A (en)	2009-03-31
TW200420567A (en)	2004-10-16
ATE387451T1 (de)	2008-03-15
BR0315756A (pt)	2005-09-06
AU2003278383A1 (en)	2004-06-07
EG24957A (en)	2011-02-28
DK1562955T3 (da)	2008-06-02
EP1562955A1 (en)	2005-08-17
KR101089462B1 (ko)	2011-12-07
KR20050074526A (ko)	2005-07-18
AR041884A1 (es)	2005-06-01
AU2003278383B2 (en)	2007-06-14
US7462623B2 (en)	2008-12-09
EP1562955B1 (en)	2008-02-27
ES2300619T3 (es)	2008-06-16
DE60319410T2 (de)	2009-02-19
MXPA05004858A (es)	2005-07-22
IS7849A (is)	2005-05-19
DE60319410D1 (en)	2008-04-10
WO2004041829A1 (en)	2004-05-21

Publication	Publication Date	Title
IL174261A0 (en)	2006-08-01	Quinazoline derivatives as tyrosine kinase inhibitors
IL174258A0 (en)	2006-08-01	Quinazoline derivatives as tyrosine kinase inhibitors
IL173200A0 (en)	2006-06-11	Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
ATE446093T1 (de)	2009-11-15	Substituierte chinazolin-derivate als aurora- kinase inhibitoren
DK1317442T3 (da)	2006-02-13	Quinolinonderivater som tyrosinkinaseinhibitorer
IS6968A (is)	2003-09-26	Nýir týrósínkínasa tálmar
DK1534290T3 (da)	2012-04-10	Hidtil ukendte kinasehæmmere
EG25942A (en)	2012-11-05	Quinazolinedione derivatives as parp inhibitors
IL186845A0 (en)	2008-02-09	Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
DE60328735D1 (de)	2009-09-17	Chinazolinderivate
IS7505A (is)	2004-10-14	Pýrróló-tríazín anilín efnasambönd gagnleg sem kínasatálmar
ATE452891T1 (de)	2010-01-15	Pyrimidopyrimidone als kinaseinhibitoren
IS7884A (is)	2005-06-09	Díasepínóindól afleiður sem kínasa hindrar
NO20050636L (no)	2005-02-04	Inhibitorer av tyrosinkinaser
AU2003298942A8 (en)	2004-06-30	Tyrosine kinase inhibitors
IS8288A (is)	2006-02-07	Hliðstæður qínazólíns sem tálmar týrósín kínasa vitaka
EP1534268A4 (en)	2006-11-02	TYROSINE KINASE INHIBITORS
IS7700A (is)	2005-02-17	Ný spíróþétt kínasólínón og notkun þeirra sem fosfórdíesterasa hindrar
EP1581539A4 (en)	2007-09-19	NEW TYROSINE KINASE HEMMER
IL164167A0 (en)	2005-12-18	4-(N-phenylamino)-quinazolines/ quinolines as tyrosine kinase inhibitors
IS7849A (is)	2005-05-19	Kínasólínafleiður sem SRC týrósínkínasatálmar
IL184798A0 (en)	2007-12-03	Quinazoline derivatives as tyrosine kinase inhibitors
IL173484A0 (en)	2006-06-11	Quinazoline derivatives as angiogenesis inhibitors
EP1651209A4 (en)	2009-03-04	TYROSINE KINASE INHIBITORS
ZA200709732B (en)	2008-11-26	Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors